Compare Global Payments Inc (GPN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Global Payments Inc trades at $80.89 (market cap $21.67B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Global Payments Inc is far larger — about 2.9× Spyre Therapeutics Inc. Common Stock's market cap, and Global Payments Inc pays a 1.22% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GPN | SYRE | |
|---|---|---|
Market Cap | $21.67B | $7.52B |
Volume | 1,851,678 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $94.83 | $108.92 |
52-Week Low | $62.47 | $22.18 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $39.81B | $6.52B |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $80.89, down 1.43% on the day, with a neutral technical outlook despite recent earnings beats. The company shows strong revenue growth momentum with Q2 2026 EPS of $3.46 beating estimates, while maintaining a P/E of 38.81 and P/B below 1.0. Recent developments include the Genius platform rollout and Worldpay integration driving business expansion.
The stock offers 27% upside to the $102.75 consensus price target with strong analyst support (59% buy ratings), though negative net income margin and rising debt-to-asset ratio to 41.57% present execution risks. Key catalysts include continued Genius adoption while competition and cost pressures remain headwinds.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
